Francesca Romano, Luisa Lanzilao, Edda Russo, Maria Infantino, Francesca Nencini, Giovanni Cappelli, Stefano Dugheri, Mariangela Manfredi, Alessandra Fanelli, Amedeo Amedei, Nicola Mucci
OBJECTIVES: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment...
March 2024: Practical Laboratory Medicine